RGLS Share Price

Open 1.40 Change Price %
High 1.43 1 Day 0.05 3.79
Low 1.33 1 Week 0.18 15.13
Close 1.37 1 Month 0.52 61.18
Volume 1207224 1 Year -2.04 -59.82
52 Week High 3.65
52 Week Low 0.79
RGLS Important Levels
Resistance 2 1.46
Resistance 1 1.42
Pivot 1.38
Support 1 1.32
Support 2 1.28
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
AAPL 156.07 -1.68%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
ALNY 113.84 51.71%
LOCM 0.09 50.00%
VALV 0.03 50.00%
HAUP 0.08 33.33%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LTRE 2.80 20.69%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
AMCF 0.01 -80.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
ORIG 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Regulus Therapeutics Inc. (NASDAQ: RGLS)

RGLS Technical Analysis 2
As on 20th Sep 2017 RGLS Share Price closed @ 1.37 and we RECOMMEND Sell for LONG-TERM with Stoploss of 1.62 & Strong Buy for SHORT-TERM with Stoploss of 1.01 we also expect STOCK to react on Following IMPORTANT LEVELS.
RGLS Target for September
1st Target up-side 1.16
2nd Target up-side 1.28
3rd Target up-side 1.39
1st Target down-side 0.84
2nd Target down-side 0.72
3rd Target down-side 0.61
RGLS Other Details
Segment EQ
Market Capital 170651968.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
RGLS Address
RGLS
N/A
RGLS Latest News
Interactive Technical Analysis Chart Regulus Therapeutics Inc. ( RGLS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Regulus Therapeutics Inc.
RGLS Business Profile
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. microRNAs are naturally occurring ribonucleic acid (RNA), molecules that play a critical role in regulating key biological pathways. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs. As of December 31, 2012 , the Company�s operations included acquiring and in-licensing intellectual property rights, developing its microRNA, undertaking basic research around microRNA targets and conducting preclinical studies for its initial programs. The Company is developing RG-101 for the treatment of HCV and is advancing other microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis and metabolic diseases.